Related Experiment Videos
Diabetic control with gliquidone--a short acting sulphonylurea
European Journal of Clinical Pharmacology
|January 1, 1984
Summary
Gliquidone and glibenclamide offer similar glycemic control for diabetics. Gliquidone achieved this without the increased risk of hypoglycemia associated with glibenclamide.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Non-insulin dependent diabetes mellitus (NIDDM) management often involves oral hypoglycemic agents.
- Comparing the efficacy and safety profiles of different oral hypoglycemic agents is crucial for optimizing patient care.
- Gliquidone and glibenclamide are both sulfonylurea drugs used in NIDDM treatment.
Purpose of the Study:
- To compare the efficacy and safety of gliquidone versus glibenclamide in NIDDM patients.
- To assess the impact of these drugs on glycemic control and hypoglycemic episodes.
- To evaluate the feasibility of tailoring drug dosages and the acceptability of self-monitoring.
Main Methods:
- A cross-over study design involving 20 patients with NIDDM.
- Utilized self-home monitoring, glycosylated hemoglobin (HbA1c), and N-acetyl-beta-D-glucosamidase levels for assessing glycemic control.
- Monitored the frequency of hypoglycemic episodes.
Main Results:
- Both gliquidone and glibenclamide demonstrated comparable glycemic control.
- Glibenclamide use was associated with a higher incidence of hypoglycemic episodes.
- Dosage tailoring indicated a frequent need for thrice-daily administration for both drugs.
- Self-glucose monitoring was found to be acceptable in a home setting.
Conclusions:
- Gliquidone provides effective glycemic control in NIDDM patients with a potentially better safety profile regarding hypoglycemia compared to glibenclamide.
- Individualized dosing, often thrice daily, is necessary for both agents.
- Home-based self-glucose monitoring is a viable tool for managing NIDDM.